Search

Your search keyword '"Hayden, Frederick G"' showing total 42 results
Start Over Author "Hayden, Frederick G" Topic viruses
42 results on '"Hayden, Frederick G"'

1. Advances in antivirals for non-influenza respiratory virus infections.

Author

Hayden FG

Subjects
Humans, Respiratory Tract Infections virology, Antiviral Agents pharmacology, Respiratory Tract Infections drug therapy, Viruses drug effects
Abstract

Progress in the development of antivirals for non-influenza respiratory viruses has been slow with the result that many unmet medical needs and few approved agents currently exist. This commentary selectively reviews examples of where specific agents have provided promising clinical benefits in selected target populations and also considers potential therapeutics for emerging threats like the SARS and Middle East respiratory syndrome coronaviruses. Recent studies have provided encouraging results in treating respiratory syncytial virus infections in lung transplant recipients, serious parainfluenza virus and adenovirus infections in immunocompromised hosts, and rhinovirus colds in outpatient asthmatics. While additional studies are needed to confirm the efficacy and safety of the specific agents tested, these observations offer the opportunity to expand therapeutic studies to other patient populations., (© 2013 Blackwell Publishing Ltd.)

Published
2013
Full Text
View/download PDF

38. Influenza A Virus-Induced Acute Otitis Media

Author

Buchman, Craig A., Doyle, William J., Skoner, David P., Post, J. Christopher, Alper, Cuneyt M., Seroky, James T., Anderson, Kenneth, Preston, Robert A., Hayden, Frederick G., Fireman, Philip, and Ehrlich, Garth D.

Published
1995

40. Influenza treatment with neuraminidase inhibitors

Author

Sander, Beate, Gyldmark, Marlene, Hayden, Frederick G., Morris, James, Mueller, Elvira, and Bergemann, Rito

Subjects
Adult, Adolescent, viruses, Cost-Benefit Analysis, Neuraminidase, Antiviral Agents, Guanidines, Decision Support Techniques, Decision modeling, Oseltamivir, Acetamides, Influenza, Human, Humans, Zanamivir, Enzyme Inhibitors, health care economics and organizations, Pyrans, virus diseases, Middle Aged, Antivirals, Original Papers, Influenza, United Kingdom, respiratory tract diseases, Treatment, Sialic Acids, Cost-effectiveness
Abstract

We assessed the cost-effectiveness and cost-utility of treating influenza with neuraminidase inhibitors (oseltamivir and zanamivir) from a health care payer's and societal perspective in the United Kingdom. A simulation model was developed to predict morbidity and mortality due to influenza and its specified complications, comparing neuraminidase inhibitors with usual care in an otherwise healthy adult population. Robustness of the results was tested by one-way and multiway as well as probabilistic sensitivity analyses. Treatment with either neuraminidase inhibitor results in reduced morbidity and faster return to normal activities. However, oseltamivir dominates zanamivir in cost-utility analysis due to its lower costs. Comparing oseltamivir with usual care, the costs are pound14.36 per day of normal activity gained and pound5,600 per quality-adjusted life-year gained from the healthcare payer perspective. Oseltamivir dominates usual care from the societal perspective. Treatment with oseltamivir is a cost-effective strategy for otherwise healthy adults in the UK from both the healthcare payer and societal perspective.

Published
2005

41. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia.

Author

Arabi, Yaseen M., Hajeer, Ali H., Luke, Thomas, Raviprakash, Kanakatte, Balkhy, Hanan, Johani, Sameera, Al-Dawood, Abdulaziz, Al-Qahtani, Saad, Al-Omari, Awad, Al-Hameed, Fahad, Hayden, Frederick G., Fowler, Robert, Bouchama, Abderrezak, Nahoko Shindo, Al-Khairy, Khalid, Carson, Gail, Taha, Yusri, Sadat, Musharaf, Alahmadi, Mashail, and Shindo, Nahoko

Subjects
IMMUNOTHERAPY, MERS coronavirus, CORONAVIRUSES, MIDDLE East respiratory syndrome, CONVALESCENT plasma, CORONAVIRUS disease treatment, COMPARATIVE studies, CORONAVIRUS diseases, ENZYME-linked immunosorbent assay, IMMUNOGLOBULINS, RESEARCH methodology, MEDICAL cooperation, MEDICAL personnel, POLYMERASE chain reaction, RESEARCH, RNA, VIRAL antibodies, EVALUATION research, REVERSE transcriptase polymerase chain reaction, NEUTRALIZATION tests
Abstract

We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested samples, 12 (2.7%) had a reactive ELISA result, and 9 of the 12 had reactive indirect fluorescent antibody and microneutralization assay titers. Undertaking clinical trials of convalescent plasma for passive immunotherapy of MERS-CoV infection may be feasible, but such trials would be challenging because of the small pool of potential donors with sufficiently high antibody titers. Alternative strategies to identify convalescent plasma donors with adequate antibody titers should be explored, including the sampling of serum from patients with more severe disease and sampling at earlier points during illness. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

42. XIth International Symposium on Respiratory Viral Infections

Author

Belser, Jessica A., Snider, Cynthia B., Cox, Nancy J., and Hayden, Frederick G.

Subjects
Meeting Reports, viruses, education, humanities, health care economics and organizations
Abstract

Please cite this paper as: Belser et al. (2011) XIth International Symposium on Respiratory Viral Infections. Influenza and Other Respiratory Viruses 5(6), 443–e457.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results